The Transgenic Mouse/ES Cell Shared Resource has been in existence since 1993 and has received continuous funding from the NCI since the Vanderbilt-lngram Cancer Center (VICC) was awarded its first Cancer Center Support Grant in 1995. At the time of the last competitive renewal, this shared resource received an """"""""Outstanding"""""""" rating. This resource provides gene targeting, DNA pronuclear microinjections, ES cell microinjections, assisted reproduction and both sperm and embryo cryopreservation services to members of the VICC. These services are essential for the generation, maintenance, and long-term storage of germline-altered mice. The resource continues to function in a multidisciplinary manner and has undergone several significant changes since the last competitive evaluation that have enabled it to continue to provide gene targeting and microinjection services at reasonable prices, to develop several new services, and to improve both its quality control and data management strategies. The Transgenic Mouse/ES Cell Shared Resource continues to offer services that remain in high demand and vital to the generation of new mouse models of cancer and other diseases. This will be critical as the gene-specific information from genome-wide cancer studies is translated to mouse models of human cancer. Moreover, the technology base that this resource supports is expected to be important in allowing Vanderbilt investigators to adapt to using of human pluripotent stem cells in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-18
Application #
8733546
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
18
Fiscal Year
2014
Total Cost
$164,559
Indirect Cost
$89,303
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Cardin, Dana B; Thota, Ramya; Goff, Laura W et al. (2018) A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Am J Clin Oncol 41:772-776
Bloodworth, Melissa H; Rusznak, Mark; Pfister, Connor C et al. (2018) Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology. J Allergy Clin Immunol 142:683-687.e12
Saito-Diaz, Kenyi; Benchabane, Hassina; Tiwari, Ajit et al. (2018) APC Inhibits Ligand-Independent Wnt Signaling by the Clathrin Endocytic Pathway. Dev Cell 44:566-581.e8
Dutter, Brendan F; Ender, Anna; Sulikowski, Gary A et al. (2018) Rhodol-based thallium sensors for cellular imaging of potassium channel activity. Org Biomol Chem 16:5575-5579
Hormuth 2nd, David A; Weis, Jared A; Barnes, Stephanie L et al. (2018) Biophysical Modeling of In Vivo Glioma Response After Whole-Brain Radiation Therapy in a Murine Model of Brain Cancer. Int J Radiat Oncol Biol Phys 100:1270-1279
Rojas, Juan D; Lin, Fanglue; Chiang, Yun-Chen et al. (2018) Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. Theranostics 8:141-155
Lewis Jr, James S; Shelton, Jeremy; Kuhs, Krystle Lang et al. (2018) p16 Immunohistochemistry in Oropharyngeal Squamous Cell Carcinoma Using the E6H4 Antibody Clone: A Technical Method Study for Optimal Dilution. Head Neck Pathol 12:440-447
Vierra, Nicholas C; Dickerson, Matthew T; Jordan, Kelli L et al. (2018) TALK-1 reduces delta-cell endoplasmic reticulum and cytoplasmic calcium levels limiting somatostatin secretion. Mol Metab 9:84-97
Schlegel, Cameron; Weis, Victoria G; Knowles, Byron C et al. (2018) Apical Membrane Alterations in Non-intestinal Organs in Microvillus Inclusion Disease. Dig Dis Sci 63:356-365
Piñeros, Marion; Frech, Silvina; Frazier, Lindsay et al. (2018) Advancing Reliable Data for Cancer Control in the Central America Four Region. J Glob Oncol :1-11

Showing the most recent 10 out of 2462 publications